High-dose cytarabine as consolidation treatment for patients with acute myeloid leukemia with t(8;21).
Seventeen patients affected by acute myeloid leukemia (AML) with t(8;21) were prospectively programmed to receive three courses of high-dose cytarabine (HDARA-C) as post-remission therapy. The median age was 39 years and in all cases t(8;21) was the only karyotypic abnormality. Complete remission (CR) was achieved in 14 out of 17 cases (82%) and, after first consolidation with NOVIA regimen (intermediate dose ARA-C plus mitoxantrone), all patients received the three planned courses of HDARA-C (3g/m(2) q12h on days 1, 3, 5). There were two documented infections, while all patients experienced fever of unknown origin (FUO). Nonhematological toxicity was mild. Thirteen out of 14 patients are in continuous CR after a median follow-up of 44 months. One patient relapsed at 16 months and, following CR2 achievement, underwent allogeneic transplantation; he died 3 months later while in CR from acute graft versus host disease (GVHD). Survival at 5 years is projected at 79%. Our data confirm the efficacy of repeated courses of HDARAC for patients with t(8;21) AML.
Palmieri
Salvatore
S
Division of Hematology, Cardarelli Hospital, Naples, Italy.
Sebastio
Lucia
L
Mele
Giuseppina
G
Annunziata
Mario
M
Annunziata
Silvana
S
Copia
Carolina
C
Viola
Assunta
A
De Simone
Mariacarla
M
Pocali
Barbara
B
Schiavone
Ettore Mariano
EM
Ferrara
Felicetto
F
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D002891:Chromosomes, Human, Pair 21; D002898:Chromosomes, Human, Pair 8; D003561:Cytarabine / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy* / Q000235:genetics* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D016019:Survival Analysis; D014178:Translocation, Genetic; D016896:Treatment Outcome
D000964:Antimetabolites, Antineoplastic; D003561:Cytarabine